Can a GLP-1 help with perimenopause belly fat?
Key takeaways
Dr. Linda's take
A patient will put it almost word for word like this: I have not really changed how I eat, but my middle is different, and the things that used to work do nothing now. She is not imagining it, and she is not failing at anything. The place her body puts fat has moved.
I want to separate two questions that usually get blended together. The first is what happens to fat during perimenopause, which is well described. The second is whether these medications do anything useful about it, which has real data behind it but comes with an honest asterisk about who was actually studied. Let me take them in order.
Why does perimenopause move fat to your belly in the first place?
Perimenopause is the stretch of progressively irregular cycles leading up to your final period, and it does something specific to fat storage.
During perimenopause, even in the context of minimal-to-modest weight gain, women experience an expansion of visceral adipose tissue, along with a reduction in gluteofemoral subcutaneous fat.
Read that closely, because it explains why the scale can mislead you. The total can barely move while the distribution changes underneath it. Fat leaves the hips and thighs and gathers in the abdomen as visceral fat around the organs.
This matters for health, not looks. This pattern of fat redistribution is associated with a greater prevalence of cardiovascular disease risk factors and a higher incidence of cardiovascular disease events.
So when your middle changes in your forties, that is not a willpower story. It is a biology story, and the biology is pointing at the exact fat depot that carries the most metabolic risk.
Does a GLP-1 actually reduce visceral belly fat?
Yes, and this is the part with solid data, though it is broader than a belly story.
In a network meta-analysis of 43 randomized trials with 3379 participants, GLP-1 receptor agonists given subcutaneously were more effective than control at decreasing total body fat, fat mass, visceral adipose tissue, subcutaneous adipose tissue, and liver fat.
Notice everything on that list. The visceral fat came down, and so did the subcutaneous fat, and the liver fat, and the total. That is the honest shape of the effect. Because both visceral and subcutaneous abdominal fat fell together in these trials, the data describe general fat loss that includes the belly, rather than a targeted shrinking of belly fat alone.
There is also direct imaging of the visceral depot. In a post hoc analysis of the STEP 6 trial, semaglutide at 2.4 mg and 1.7 mg reduced visceral fat area compared with placebo across all subgroups examined.
Can it bring your waist measurement down?
Waist size is the everyday stand-in for visceral fat, and it moves too.
Across the STEP 1 to 3 and STEP 5 trials, semaglutide at 2.4 mg produced greater reductions from baseline than placebo in body weight and waist circumference.
For a sense of scale on weight itself, in the STEP 1 trial, once-weekly semaglutide at 2.4 mg reduced body weight by 14.9% from baseline over 68 weeks, compared with 2.4% in the placebo group.
The waist tracks the same direction. In a post hoc analysis of SURMOUNT-1, after 72 weeks of tirzepatide at 10 or 15 mg, 54.7% of participants improved their baseline waist-to-height ratio category, compared with 9.6% on placebo.
None of this is spot treatment of the belly. It is whole-body fat loss, and because the perimenopausal middle is made largely of visceral and abdominal fat, that is the part you tend to see change.
What has to stay honest about who was studied and how it works?
Two things I refuse to blur.
First, the population. Most of these trials enrolled broad groups of adults with excess weight, not women selected for perimenopause. The STEP 1 trial enrolled 1961 adults with obesity, or overweight with at least one weight-related condition, who did not have diabetes. None of the visceral-fat findings above were generated in a trial built specifically around the menopause transition, so I am reporting a well-supported general effect and telling you plainly that it has not been isolated to perimenopausal women.
Second, muscle. In the same network meta-analysis, no significant change in total lean tissue was seen overall, but lean mass fell from baseline at higher doses, including liraglutide at 1.8 mg daily, semaglutide at 1.0 mg weekly, and tirzepatide at 15 mg weekly. That is one reason fast fat loss without attention to strength can cost you, and it matters more during the menopause transition. We go into it in protecting muscle while losing weight in perimenopause.
How does this fit the rest of your perimenopause decisions?
The visceral-fat question rarely arrives alone. If you are also weighing hormone therapy, the two decisions interact, and we walk through hormone therapy alongside a weight medication in perimenopause. If your cycles are shifting at the same time, whether your periods might change in perimenopause is a companion piece.
If you want a starting point for whether any of this fits your situation, our eligibility quiz is one place to begin. It is general education, not a plan for you specifically.
The honest bottom line
Can these medications help with perimenopause belly fat? The visceral fat that defines the transition does come down when total fat comes down, and the trial data on visceral fat, waist, and waist-to-height ratio are genuinely consistent. That is real, and I do not want to undersell it.
What I will not sell you is a belly-only miracle. There is no spot reduction, the effect is whole-body fat loss that happens to include the depot you notice most, and the studies were run in general populations rather than in women chosen for the menopause transition. Perimenopause is already a season of being told your body is a problem to fix. I would rather hand you an accurate picture of what moves, and why, so you can decide with your eyes open.
Frequently asked questions
Does a GLP-1 target belly fat specifically?
Not specifically. There is no spot reduction. In trials, both visceral and subcutaneous abdominal fat fell together, so the belly changes as part of general fat loss rather than as a targeted effect on one area.
Does semaglutide reduce visceral fat?
Yes. In a post hoc analysis of the STEP 6 trial, semaglutide at 2.4 mg and 1.7 mg reduced visceral fat area compared with placebo across all subgroups examined. Visceral fat is the deep abdominal fat that expands most in perimenopause.
How much weight did people lose on semaglutide?
In the STEP 1 trial, once-weekly semaglutide at 2.4 mg reduced body weight by 14.9% from baseline over 68 weeks, compared with 2.4% in the placebo group. Bear in mind those participants were adults with obesity in general, not perimenopausal women specifically.
Were these medications tested in perimenopausal women?
Mostly no. The STEP 1 trial enrolled 1961 adults with obesity, or overweight with at least one weight-related condition, who did not have diabetes. The visceral-fat and waist findings come from broad populations, so they describe a general effect rather than a perimenopause-specific one.
Will a GLP-1 also cost me muscle?
It can, especially at higher doses. In a network meta-analysis, lean mass fell from baseline at higher doses, including liraglutide at 1.8 mg daily, semaglutide at 1.0 mg weekly, and tirzepatide at 15 mg weekly. Protecting muscle with strength work and enough protein is part of doing this well, which is why we cover it on its own.
References
1. American journal of preventive cardiology (2026). Perimenopause as an obesogenic sensitive period: Contributions to elevated cardiovascular risk. PubMed PMID 41567597. https://pubmed.ncbi.nlm.nih.gov/41567597/ (Accessed 2026-07-18).
2. Diabetes, obesity & metabolism (2026). Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials. PubMed PMID 42209204. https://pubmed.ncbi.nlm.nih.gov/42209204/ (Accessed 2026-07-18).
3. Obesity research & clinical practice (2025). Effect of once-weekly subcutaneous semaglutide on abdominal visceral fat area in Japanese adults with overweight and obesity: A post hoc analysis of the STEP 6 trial. PubMed PMID 40189961. https://pubmed.ncbi.nlm.nih.gov/40189961/ (Accessed 2026-07-18).
4. Postgraduate medicine (2022). Cardiometabolic risk factors efficacy of semaglutide in the STEP program. PubMed PMID 36691308. https://pubmed.ncbi.nlm.nih.gov/36691308/ (Accessed 2026-07-18).
5. The New England journal of medicine (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. PubMed PMID 33567185. https://pubmed.ncbi.nlm.nih.gov/33567185/ (Accessed 2026-07-18).
6. Journal of endocrinological investigation (2026). Shifts in waist-to-height ratio categories within tirzepatide groups: a post-hoc analysis of SURMOUNT-1. PubMed PMID 42082865. https://pubmed.ncbi.nlm.nih.gov/42082865/ (Accessed 2026-07-18).
---
*This article is general education and is not medical advice. It cannot tell you what is right for your body. Talk with a licensed clinician about your own situation.*
*Written and clinically reviewed by Dr. Linda Moleon, MD. Last reviewed 2026-07-18.*
Keep reading
How much weight can you lose on retatrutide?
Retatrutide is investigational, but its phase 2 trial is striking Ā· the highest 12-mg dose cut body weight a mean 24.2% at 48 weeks. Dr. Linda lays out the real numbers, the context against approved options, and why phase 2 results can still shift.
Can you take a GLP-1 if you have hypothyroidism?
Treated hypothyroidism is not a reason to rule out a GLP-1, and the boxed warning is about a rare thyroid cancer, not an underactive gland Ā· but because these medicines slow gastric emptying, levothyroxine absorption is worth monitoring with a clinician.
Can a GLP-1 lower heart disease risk after menopause?
The SELECT trial found semaglutide lowered major cardiovascular events by 20% in people with established heart disease and obesity without diabetes Ā· but it was not a menopause trial, so Dr. Linda explains where the evidence is solid and where it is extrapolated.
Were Black and Latina women included in GLP-1 weight-loss trials?
Black and Latina women were enrolled in the major semaglutide and tirzepatide weight-loss trials, and subgroup analyses found the medicines worked across race and ethnicity Ā· but non-white participants were under-represented relative to disease burden.
Does a GLP-1 lower testosterone in women with PCOS?
GLP-1 medicines are linked to a modest, mostly indirect drop in testosterone and free androgen index in women with PCOS, with the biggest shifts when paired with metformin. Dr. Linda explains the evidence and the honest limits.
How much muscle do you lose on a GLP-1, and can you get it back?
Some of the weight lost on a GLP-1 is muscle, not just fat. Dr. Linda Moleon, MD on how much lean mass the trials show, whether it comes back after stopping, and the two things that actually protect it.